$0.01
(0.78%)
Add to watchlist
Create an alert
Stocks and Shares ISAAIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Company Information
About this company
Key people
Thomas K. Equels
President, Chief Executive Officer, Executive Vice Chairman of the Board
Robert Dickey
Chief Financial Officer
Peter W. Rodino
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
William M. Mitchell
Independent Chairman of the Board
Nancy K. Bryan
Independent Director
David I. Chemerow
Independent Director
Ted D. Kellner
Independent Director
Click to see more
Key facts
- Shares in issue2.85m
- EPICAIM
- ISINUS00901B3033
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.68m
- Employees21
- ExchangeNyse American LLC
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.